The lawsuit claims that between August 9, 2024, and March 25, 2026, ADMA Biologics artificially inflated its stock price by concealing related-party transactions and utilizing channel stuffing to manufacture the appearance of revenue growth. According to the complaint, these practices occurred alongside a lack of adequate internal controls, misleading investors about the company’s underlying business health.
In section Releases
Investors Face August 10 Deadline in ADMA Biologics Fraud Suit
August 10 marks the final window for ADMA Biologics investors to apply as lead plaintiffs in a class action lawsuit. The litigation, spearheaded by Hagens Berman, targets alleged financial misrepresentations that triggered a sharp decline in shareholder value following a series of corrective disclosures earlier this year.
The market reacted violently to these revelations in March 2026. Following a report from Culper Research that detailed undisclosed ties to distributor Genesis BioPharma, ADMA shares plummeted 31.6% over two trading days. A subsequent press release from the company and a downgrade from Cantor Fitzgerald pushed the stock down another 13.9%, leaving investors with significant losses. Hagens Berman partner Reed Kathrein is currently leading the investigation into whether the company’s public statements lacked a reasonable basis, urging those with substantial losses or non-public information to contact the firm before the court-imposed deadline.
Comments (0)
No comments yet. Be the first!